{'fraction_non_alphanumeric': 0.01291248206599713, 'fraction_numerical': 0.0028694404591104736, 'mean_word_length': 4.915254237288136, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacological aspects of clinical stage I/II trials with human beta interferon in children.

ABSTRACT Serum levels of IFN have been tested using various routes of administration of IFN-γ in patients. No IFN was detectable in the serum after intramuscular or subcutaneous injection. Intravenous injections led to periods of serum levels which were much shorter than those seen after the intramuscular injection of IFN-γ. Infusions over 30 min seemed to be the best compromise between the achieved peak level and the duration of detectable IFN levels. A clear linear relationship between peak serum level and dose was established under these conditions when the body surface was used as parameter.